This pivotal trial will assess the efficacy of Celeste®, the company’s FDA Breakthrough phototherapy device to improve non-motor and motor function and quality of life in Parkinson’s disease (PD). The Celeste device builds on the company’s innovative Spectramax™ technology that has been successfully used in previous human research. This 300-patient phototherapy trial will be the largest trial of its kind.

Kent Savage, President and CEO of PhotoPharmics, underlined the importance and anticipation surrounding the trial. "After overcoming funding challenges and delays caused by the global pandemic, we are thrilled to launch this trial, which holds immense promise for those affected by Parkinson's Disease," he stated. The trial follows the FDA’s Breakthrough Device Designation for the Celeste® device in April 2020, acknowledging its potential in treating PD.

The post Largest Phototherapy Trial for Parkinson’s Disease appeared first on PhotoPharmics.

The primary purpose of this investment round is to fund a pivotal clinical trial aimed at obtaining FDA market authorization for Celeste PhotoPharmics' FDA breakthrough therapeutic device for Parkinson's disease. In research to this point, the innovative therapy has shown remarkable potential in improving overall function and quality of life for people with Parkinson's disease.

Kent Savage, CEO of PhotoPharmics, expressed his gratitude for the support of investors, stating, "This investment is a pivotal moment in our journey to transform the treatment landscape for Parkinson's disease. With this funding, we are positioned to advance our research and bring hope to the millions of individuals living with Parkinson's."

The post Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease appeared first on PhotoPharmics.

According to event organizers, DeviceTalks Boston is designed to provide valuable insights in easy-to-identify tracks, for funding and leading start-ups, engineering and developing new prototypes and devices, manufacturing medical devices with new materials and technologies, and bringing new products to market through regulatory, reimbursement, and commercial challenges.

The post PhotoPharmics to Present at MTI All Stars Investor Showcase appeared first on PhotoPharmics.

The post PhotoPharmics brings renowned experts in Parkinson’s disease and other neurodegenerative diseases to advisory board appeared first on PhotoPharmics.

“We are delighted to welcome Dr. Kieburtz to lead our clinical development," said Kent Savage, President & CEO of PhotoPharmics. "He has an extensive track record in Parkinson’s disease and is a proven leader in central nervous system disorders. His insight and expertise will be invaluable to PhotoPharmics as we advance development of our therapies in Parkinson’s disease and other neurodegenerative diseases."

The post PhotoPharmics Appoints Dr. Karl Kieburtz as Chief Medical Officer appeared first on PhotoPharmics.

“We’re delighted with this designation and honor,” said Kent Savage, CEO of PhotoPharmics. “International attention from leading organizations like MedTech brings us closer to delivering on our mission of innovation, particularly providing a breakthrough, non-invasive treatment for people suffering from the symptoms of Parkinson’s disease.”

“We’re seeing a real breakthrough here,” said Savage. “Once approved, this may be the first therapy to address non-motor problems in Parkinson's, one that we feel promises a nearly 5-year reversal of symptom progression—based on the results of our last clinical trial.”

The post Utah-based PhotoPharmics Selected as Global Top 50 Startup appeared first on PhotoPharmics.